Plerixafor

• CAS Number:

  110078-46-1

• UNSPSC Description:

  Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM[1][2][3][4][7].

• Target Antigen:

  CXCR; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;GPCR/G Protein;Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Endocrinology; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Plerixafor.html

• Purity:

  99.90

• Solubility:

  DMSO : 1.92 mg/mL (ultrasonic;warming;adjust pH to 7 with 1 M HCL;heat to 60°C)|Ethanol : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  C1(CN2CCCNCCNCCCNCC2)=CC=C(C=C1)CN3CCNCCCNCCNCCC3

• Molecular Weight:

  502.78

• References & Citations:

  [1]Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009 Sep 1;183(5):3204-11.|[2]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.|[3]Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11(2):e0149926.|[4]Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10(7):e0133616.|[5]De Clercq E, et al. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382.|[6]Seki JT, et al. Chemical Stability of Plerixafor after Opening of Single-Use Vial. Can J Hosp Pharm. 2017 Jul-Aug;70(4):270-275.|[7]Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71(2-3):216-26.|[8]Zheng J, et al. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther. 2019;18:1534735419862352.ACS Infect Dis. 2023 Oct 5.|Acta Biomater. 2024 Feb 13:S1742-7061(24)00067-9.|Acta Biomater. 2024 Jul 17:S1742-7061(24)00395-7.|Andrology. 2022 Sep 16.|Bioact Mater. 2021 Jan 7;6(7):2039-2057.|Biochem Biophys Res Commun. 2021 Jan 1;534:337-342.|Biomed Pharmacother. 2020, 110610.|Biomolecules. 2024 Sep 25;14(10):1206.|BMC Complement Altern Med. 2018 Dec 12;18(1):330. |Br J Haematol. 2022 Dec 19.|Cancer Lett. 2022 Oct 7;551:215944.|Cell Death Dis. 2017 Jan 19;8(1):e2560. |Cell Death Dis. 2022 Feb 4;13(2):118.|Cell Death Dis. 2023 Mar 28;14(3):219.|Cell Mol Immunol. 2020 Mar;17(3):283-299.|Cell Mol Life Sci. 2024 Mar 13;81(1):132.|Cell Physiol Biochem. 2018;46(3):890-906. |Cell Signal. 2020 Feb;66:109488.|Cell Tissue Res. 2020 Jun;380(3):469-486.|Cell Transplant. 2022 Jan-Dec;31:9636897221129171.|Cells. 2019 Jul 22;8(7):761.|Cells. 2022 Jan 4;11(1):155.|Chinese Journal of Tissue Engineering Research. 2014,18(45): 7327-7332.|Drug Des Devel Ther. 2022 Jan 6;16:67-81.|Exp Ther Med. July 19, 2021.|Fertil Steril. 2020 May;113(5):1067-1079.e5.|Immunity. 2024 Feb 13;57(2):364-378.e9.|Int J Biol Sci. 2017 May 5;13(5):604-614.|Int J Mol Sci. 2023 Aug 13, 24(16), 12740.|Int J Mol Sci. 2024 Jul 1;25(13):7254.|Int J Mol Sci. 2024 May 4;25(9):5018.|Int J Nanomedicine. 2023 Jul 31;18:4329-4346.|J Diabetes Complicat. 2020 Oct;34(10):107654.|J Mater Chem B. 2018 Apr 7;6(13):1951-1964. |J Oncol. 08 Oct 2021.|J Steroid Biochem Mol Biol. 2021 Jun 3;105926.|J Transl Med. 2023 Sep 5;21(1):593.|Kaohsiung J Med Sci. 2021 Nov 6.|Ludwig maxime clinic. University of Munich. 2019 Apr.|Mol Med Rep. 2020 Oct;22(4):3201-3212.|Nano Today. 2022, 47: 101689.|Nat Cell Biol. 2024 Jul 22.|Oncogene. 2019 Jun;38(25):5021-5037. |Oncol Lett. 2018 Sep;16(3):3976-3982. |Patent. US20200360478A1.|PLoS One. 2021 Mar 1;16(3):e0247707.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2022 Jul.|Research Square Preprint. 2023 Oct 23.|SSRN. 5 Feb 2022.|Stem Cells Int. 2020 Jul 7;2020:1498315.|Theranostics. 2021 Jan 1;11(6):2612-2633.|Transl Stroke Res. 2021 Jun 25.|Universität Hamburg. Informatics and Natural Sciences. 2021 Mar 19.|University of Zagreb. 2024 May 23.|Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.|Adv Funct Mater. 2020, 2000309.|Anticancer Drugs. 2017 Oct;28(9):935-942.|Brain Behav Immun. 2017 Jan;59:322-332.|Mater Today Bio. 2024 Sep 1:28:101222.|Mol Ther-Nucl Acids. 2023 Mar 9.|Oncogene. 2022 Oct;41(41):4633-4644.|Oxid Med Cell Longev. 2021 Aug 2;2021:9993240.|Patent. US20190133998A1.|Pharmaceutics. 2021 Mar 24;13(4):439.|Ruprecht-Karls-University Heidelberg. 2023 Aug 3.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched